Interleukin-6 signalling, lipoprotein (a) lowering and cardiovascular disease: a mendelian randomisation study

Back

ESC Professional Premium Access

Interleukin-6 signalling, lipoprotein (a) lowering and cardiovascular disease: a mendelian randomisation study

Session: Dyslipidaemia: novel diagnostics and therapy options

Topic: Drug therapy

Speaker: Doctor S. Brennan (Dublin, IE)

Event: ESC Congress 2024

Congress Presentation

Add to my library

About the speaker

Doctor Stephen Brennan

Mater Misericordiae University Hospital, Dublin (Ireland)

0 follower

5 more presentations in this session

Comparative efficacy of colchicine and intensive LDL-C lowering in patients with ASCVD receiving statins: a network meta-analysis of randomised controlled trials

Speaker: Doctor Z. Ou (Chongqing, CN)

Deciphering lipoprotein(a) atherogenicity with use of high-throughput proteomics

Speaker: Doctor J. Morze (Gothenburg, SE)

The upfront lipid-lowering combination therapy of statins and ezetimibe vs statin monotherapy in the reduction of cardiovascular outcomes. A meta-analysis.

Speaker: Professor M. Banach (Lodz, PL)

Contemporary LDL-cholesterol management in male and female patients at high-cardiovascular risk: results from the European observational SANTORINI study

Speaker: Professor D. Nanchen (Lausanne, CH)

The change of paradigm: high HDL-c levels could not mean a long lifespan

Speaker: Doctor F. Sousa (Funchal, PT)

Access the full session

Dyslipidaemia: novel diagnostics and therapy options

Speakers: Doctor S. Brennan, Doctor Z. Ou, Doctor J. Morze, Professor M. Banach, Professor D. Nanchen...

Access

Video

About the event

ESC Congress 2024

30 August - 2 September 2024

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources